Clinical Trial

Pilot Trial of Colchicine for Graft Failure in CABG

Study acronym: CoCAB-Pilot
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG. The main questions it aims to answer is: 1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG. 2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis. Researchers will compare colchicine to none to see if colchicine works. Participants will 1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG. 2. Clinical follow-up at Month 1, 6, and 12 after CABG. 3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-30; most recent amendment 2025-12-29.
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT06802926
Lead Sponsor Ruijin Hospital
Conditions CABG, Graft Failure, Colchicine
Enrollment 100 participants
Start Date 2025-12-29
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-02